Yazılar

Corning Partners with U.S. Solar Manufacturers to Produce All-American Solar Panels

/in /tarafından

Corning, a global technology company, has announced a partnership with U.S. solar manufacturers Suniva and Heliene to produce the only solar panels made entirely from American-made components. This collaboration marks a significant step in strengthening the U.S. solar manufacturing sector, which aims to compete with China in the global market.

Georgia-based Suniva, which specializes in solar cells, and Heliene, a panel manufacturer based in Canada with production facilities in Minnesota, will combine their efforts with Corning. Corning, along with its subsidiary Hemlock Semiconductor, produces key materials for solar panels, including silicon wafers and polysilicon, in Michigan.

AB Ghosh, Corning’s vice president and general manager of solar technologies, emphasized the company’s excitement about leveraging its advanced manufacturing capabilities to enhance the quality of solar components while securing the U.S. energy supply chain.

This partnership comes as part of a broader effort to bolster U.S. solar manufacturing, driven in part by tax incentives in the 2022 Inflation Reduction Act, which has fueled the growth of clean energy factories across the country. Despite shifts in the political landscape, clean energy companies continue to push for policies that not only address climate change but also support American energy production and job creation.

The new solar panel module will feature up to 66% domestic content, the highest of any solar panel currently on the market. This product will help solar developers qualify for a 10% domestic content tax credit on top of the 30% base credit provided by the Inflation Reduction Act.

Medicare Drug Price Negotiations: Short-Term Stability, Long-Term Concerns for Pharma

/in /tarafından

The conclusion of the first round of Medicare drug price negotiations marks a significant milestone, though the final negotiated prices for the selected medications remain undisclosed. These prices, set to be revealed in early September, will come into effect in 2026. While the pharmaceutical industry continues to view these negotiations as a long-term threat to innovation and profits, there appears to be a sense of short-term stability among drugmakers based on recent earnings calls from key companies like Bristol Myers Squibb, Johnson & Johnson, and others.

Executives from major pharmaceutical companies have expressed varying degrees of confidence regarding the immediate impact of these negotiations. Bristol Myers Squibb CEO Christopher Boerner mentioned that the company has received the final price for its blood thinner Eliquis, shared with Pfizer, and is “increasingly confident” in navigating the impact. AbbVie CEO Robert Michael noted that the expected sales impact on its leukemia drug Imbruvica is included in financial forecasts, with AbbVie still expecting to meet its long-term outlook. Similarly, J&J Worldwide Chairman Jennifer Taubert expressed confidence in the company’s long-term growth despite new prices for its blood thinner Xarelto and psoriasis treatment Stelara.

However, Novartis CEO Vasant Narasimhan acknowledged that while the short-term impact on its drugs, such as the heart failure drug Entresto, might be manageable, the policy’s long-term effects are concerning. Narasimhan criticized the policy for its negative implications on innovation and patient care.

Despite the immediate stabilization, the pharmaceutical industry remains strongly opposed to Medicare drug price negotiations, labeling them as bad public policy. Executives like Boerner from Bristol Myers Squibb highlighted concerns about the long-term implications on innovation due to the Inflation Reduction Act (IRA). Legal challenges from companies like Merck and Novartis are ongoing, with similar claims from other industry players and trade groups being recently rejected.

The Medicare drug price negotiation authority, established under President Joe Biden’s Inflation Reduction Act, aims to make medications more affordable for older Americans. While the immediate concerns over the new Medicare drug prices have somewhat subsided, the pharmaceutical industry remains wary of the long-term impacts. The upcoming price disclosures in September will provide clearer insights into how these negotiations will shape the market and influence future strategies for drugmakers.

US Government’s Proposal to Boost EV Sales: Challenges and Opportunities

/in /tarafından

The US government is set to overhaul auto emissions standards, mandating that electric vehicles (EVs) constitute approximately two-thirds of all new car sales by 2032. According to Moody’s analyst Matthias Heck, achieving these targets will be challenging but feasible with significant investment. The proposal remains tentative and could be revised before finalization.

In the coming decade, advancements in battery technology, reduced costs, and government incentives like those from the Inflation Reduction Act will make EVs more attractive to consumers. Chris Harto of Consumer Reports highlights that while EVs are expected to gain substantial market share, the transition will not be abrupt; gas-powered vehicles will still dominate the roads in 2032. However, improved driving ranges, faster charging, and lower operating costs will make EVs more appealing.

Moody’s predicts that next-generation batteries will offer 30% greater range and faster charging, which, coupled with enhanced charging infrastructure, should ease consumer adoption. By 2026, JD Power’s Elizabeth Krear anticipates that EV equivalents will cover 75% of available models, with market share growing to 27%. California, already a leader in EV adoption, is expected to reach two-thirds market share for EVs before 2032, driven by its stringent policies and large market size.

Despite these promising developments, achieving the 2032 goal is not guaranteed. The increasing entry of automakers into the EV market and evolving consumer preferences will play crucial roles. Brands like Toyota and Honda are expanding their EV offerings, with GM aiming to transition to an all-electric lineup by 2035. The Alliance for Automotive Innovation has urged careful planning and collaboration to ensure success.

As the market shifts, automakers that lag in EV adoption may face economic pressures to adapt, making the widespread acceptance of EVs a likely outcome.